TriptorelinGnRH agonist
Triptorelin is a GnRH agonist used in condition-specific hormone-suppression care. Its depot formulations maintain exposure over time, but the clinical meaning depends on the disease and the exact product.
What is Triptorelin?
Triptorelin is a GnRH agonist available in depot formulations for defined hormone-suppression uses, including prostate cancer and central precocious puberty in product-specific settings. 1 2
How it works
Sustained receptor stimulation initially increases, then downregulates, pituitary LH and FSH signalling. The resulting fall in sex hormones underlies the treatment effect. 2
Effects studied
Testosterone suppression in prostate cancer
Clinical studies assess how consistently a formulation suppresses testosterone. That biochemical endpoint is not equivalent to a demonstrated survival advantage over another treatment.
Evidence: Formulation-specific clinical trial. 1
What does the evidence show?
Prostate-cancer comparison and product-label lead
An initial stimulus followed by suppression
Triptorelin acts at pituitary GnRH receptors. Repeated or sustained exposure eventually reduces LH and FSH signalling and the production of downstream sex hormones. The initial stimulation can create a temporary flare, so the time course matters as well as the eventual hormone level.
Why the intended outcome must be named
In prostate cancer, lowering testosterone reduces androgen stimulation of susceptible cancer. In paediatric care, a different product and protocol may suppress central precocious puberty. These purposes need separate evidence; neither is adequately described as improving hormonal health.
What the trial comparison tells us
The retained comparative study examines triptorelin and another GnRH-agonist strategy in prostate cancer. Hormone suppression is a useful endpoint, but comparisons of testosterone levels do not necessarily establish differences in survival, cardiovascular risk or quality of life. Those need direct measurement over an appropriate period. 1
The longer-term balance
Reduced sex-hormone exposure can affect bone, sexual function, metabolic health and wellbeing. Injection effects and the practical demands of a depot formulation also matter. Indications and monitoring need to follow the current local label. A longer gap between administrations does not lessen the importance of these biological effects. 2
Safety & status
Initial hormonal flare, injection effects and the longer-term consequences of sex-hormone suppression matter. Bone, metabolic and sexual health may require monitoring. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Are different depot products interchangeable?
No. Release duration and indication belong to the exact product and its instructions. 2
Why can symptoms initially worsen with an agonist?
The early stimulation can temporarily increase hormones before sustained suppression develops. 2
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.